Drawing on her expertise, Dr. Zinaï will be supporting Tollys in its early clinical developments.
Professor Jean-Yves Blay, current member of the scientific advisory board, takes up chairmanship as company prepares to launch clinical programs.
With more than 35 years experience in the pharmaceutical industry and biotech, Philippe Goupit will lead Tollys’ plans for growth.
Bettina Werle will supervise the laboratory, help set its scientific priorities and lead Tollys’ R&D team.
Support funding for breakthrough innovation will help company’s development in preparation for clinical trials in bladder cancer
Funds will further development of a new cancer immunotherapy: synthetic TLR3 agonist TL-532.
Three senior industry executives join the board of directors.